Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerJulie R. Brahmer, Jon M. Wigginton, Scott S. Tykodi et al.|New England Journal of Medicine|2012Cited by 8k
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerMohamed A. Gouda, Funda Meric‐Bernstam, Scott S. Tykodi et al.|ESMO Open|2025Cited by 54